The RightMed Test is a PGx test that offers comprehensive coverage backed by rigorous curation of high-level, scientific evidence to give providers and their patients confidence in test results. The RightMed Test covers 27 genes that may impact how a patient responds to certain medications used to treat various conditions including psychiatric conditions, cancer, cardiovascular disease, pain, and more.

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. OneOme’s RightMed solution offers tailored products and services that meet the needs of payers, healthcare organizations, providers, and patients. At the core of the RightMed solution is the RightMed test, which provides genetic information that doctors can use to identify how a patient’s DNA may affect his or her response to hundreds of medications. OneOme pairs the RightMed test with a suite of tools and services including the OneOme portal, no-cost clinical consults with expert PharmDs, training and education, population tools, and more.

Driven by the Sequence Once, Query OftenTM model, population genomics with Helix allows health systems to uncover genetic risk more efficiently and utilize genetic insights at the point-of-care. Leading health systems have seen these programs improve care, address health inequities and engage patients & providers, all while reducing costs.

Helix is the leading population genomics and viral surveillance company. Helix enables health systems, public health organizations and life sciences companies to accelerate the integration of genomic data into patient care and public health decision making. Learn more at www.helix.com.